MARKET

ORMP

ORMP

Oramed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.493
-0.177
-6.64%
Opening 14:23 11/19 EST
OPEN
2.700
PREV CLOSE
2.670
HIGH
2.730
LOW
2.490
VOLUME
69.45K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
2.317
MARKET CAP
43.33M
P/E (TTM)
-2.8614
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ORMP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ORMP News

  • Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event
  • PR Newswire.5h ago
  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.4d ago
  • Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th
  • PR Newswire.5d ago
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.6d ago

More

Industry

Biotechnology & Medical Research
+2.18%
Pharmaceuticals & Medical Research
+0.77%

Hot Stocks

Name
Price
%Change

About ORMP

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.
More

Webull offers Oramed Pharmaceuticals, Inc. (ORMP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.